Figure 4.

Effects of Oxamate alone or in Combinations with Pembrolizumab on NSCLC Hu-PBMC-CDX. (A) Experimental timeline for treatment NSCLC CDX with Oxamate and pembrolizumab in Hu-PBMC-B-NDG mice. (B) Tumor growth curve of control group, Oxamate monotherapy group, Pembrolizumab monotherapy group and combination treatment group. Data are presented as the mean ± SD of the volume of CDX (mm³); n = 5. *P<0.05, ***P<0.001. (C) The body weight of mice in each treatment group and normal mice without PBMCs transplantation was monitored every four days from the beginning of PBMCs transplantation to the end of treatment; n=5. (D, E) At the end of treatment, the tumors of each treatment group were collected, photographed and weighed; n = 5. *P<0.05, ***P<0.001 (F) Tumour growth after treated with Oxamate or PBS in B-NDG mice bearing NSCLC cell line. Group mean differences between Oxamate vs. controls were not significant; n = 5.